Literature DB >> 29568097

Minimal residual disease (MRD) monitoring and mutational landscape in AML with RUNX1-RUNX1T1: a study on 134 patients.

Alexander Höllein1, Sabine Jeromin1, Manja Meggendorfer1, Annette Fasan1, Niroshan Nadarajah1, Wolfgang Kern1, Claudia Haferlach1, Torsten Haferlach2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29568097     DOI： 10.1038/s41375-018-0086-0

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  7 in total

1.  MRD evaluation of AML in clinical practice: are we there yet?

Authors:  Sylvie D Freeman; Christopher S Hourigan
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

2.  Molecular characterization of AML with RUNX1-RUNX1T1 at diagnosis and relapse reveals net loss of co-mutations.

Authors:  Alexander Höllein; Niroshan Nadarajah; Manja Meggendorfer; Sabine Jeromin; Wolfgang Kern; Claudia Haferlach; Torsten Haferlach
Journal:  Hemasphere       Date:  2019-02-04

Review 3.  The power and potential of integrated diagnostics in acute myeloid leukaemia.

Authors:  Torsten Haferlach; Ines Schmidts
Journal:  Br J Haematol       Date:  2019-12-06       Impact factor: 6.998

4.  Case Report: Preemptive Treatment With Low-Dose PD-1 Blockade and Azacitidine for Molecular Relapsed Acute Myeloid Leukemia With RUNX1-RUNX1T1 After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Yutong Tang; Zhenyang Zhou; Han Yan; Yong You
Journal:  Front Immunol       Date:  2022-02-02       Impact factor: 7.561

Review 5.  Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML).

Authors:  Kelly Mitchell; Ulrich Steidl
Journal:  Cold Spring Harb Perspect Med       Date:  2020-01-02       Impact factor: 6.915

6.  Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.

Authors:  Guan-Hua Hu; Yi-Fei Cheng; Ai-Dong Lu; Yu Wang; Ying-Xi Zuo; Chen-Hua Yan; Jun Wu; Yu-Qian Sun; Pan Suo; Yu-Hong Chen; Huan Chen; Yue-Ping Jia; Kai-Yan Liu; Wei Han; Lan-Ping Xu; Le-Ping Zhang; Xiao-Jun Huang
Journal:  BMC Cancer       Date:  2020-06-15       Impact factor: 4.430

Review 7.  Core binding factor acute myelogenous leukemia-2021 treatment algorithm.

Authors:  Gautam Borthakur; Hagop Kantarjian
Journal:  Blood Cancer J       Date:  2021-06-16       Impact factor: 11.037
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.